Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) Director Janet Napolitano sold 3,200 shares of Vir Biotechnology stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the transaction, the director owned 21,216 shares of the company’s stock, valued at approximately $200,491.20. This trade represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vir Biotechnology Trading Down 3.2%
NASDAQ:VIR opened at $8.74 on Wednesday. The firm has a market cap of $1.47 billion, a PE ratio of -2.79 and a beta of 1.65. The stock has a fifty day moving average price of $9.49 and a 200 day moving average price of $7.96. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $11.66.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.84). The company had revenue of ($0.03) million during the quarter, compared to analysts’ expectations of $55.49 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. During the same quarter last year, the business posted ($0.88) earnings per share. Equities analysts forecast that Vir Biotechnology, Inc. will post -1.75 EPS for the current year.
Institutional Trading of Vir Biotechnology
Wall Street Analyst Weigh In
A number of research firms recently issued reports on VIR. HC Wainwright lifted their target price on Vir Biotechnology from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Needham & Company LLC lifted their target price on Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Morgan Stanley set a $23.00 target price on Vir Biotechnology in a report on Friday, May 8th. Evercore restated an “outperform” rating and issued a $18.00 price target on shares of Vir Biotechnology in a research note on Tuesday, February 24th. Finally, Wall Street Zen cut Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average price target of $20.25.
Read Our Latest Research Report on Vir Biotechnology
About Vir Biotechnology
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Read More
- Five stocks we like better than Vir Biotechnology
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
